In addition to T2DM, PIO use has increased in other therapeutic areas such as non-alcoholic fatty liver disease, atherosclerosis, inflammation, infertility, and cancer due to the wide spectrum of effects secondary to PPARγ activation (Cariou et al., 2012; Yau et al., 2013). This evidence concerns the gene PPARG and type 2 diabetes mellitus.